TSWM
VRTX icon

Triangle Securities Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Triangle Securities Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$849K Hold
1,709
– – 0.17% 125
2026
Q1 		$763K Hold
1,709
– – 0.17% 125
2025
Q4 		$775K Sell
1,709
-27
-2% -$11.6K 0.16% 127
2025
Q3 		$680K Buy
1,736
+8
+0.5% +$3.34K 0.15% 138
2025
Q2 		$769K Buy
1,728
+10
+0.6% +$4.61K 0.19% 120
2025
Q1 		$833K Sell
1,718
-48
-3% -$22.4K 0.21% 117
2024
Q4 		$711K Sell
1,766
-19
-1% -$8.81K 0.18% 129
2024
Q3 		$830K Sell
1,785
-45
-2% -$21.6K 0.21% 121
2024
Q2 		$858K Sell
1,830
-20
-1% -$8.68K 0.24% 114
2024
Q1 		$773K Sell
1,850
-43
-2% -$18.2K 0.22% 119
2023
Q4 		$770K Sell
1,893
-98
-5% -$36.2K 0.24% 113
2023
Q3 		$692K Sell
1,991
-159
-7% -$55.6K 0.25% 110
2023
Q2 		$757K Sell
2,150
-200
-9% -$67.4K 0.26% 111
2023
Q1 		$740K Sell
2,350
-58
-2% -$17.4K 0.26% 110
2022
Q4 		$695K Sell
2,408
-450
-16% -$137K 0.25% 113
2022
Q3 		$828K Sell
2,858
-205
-7% -$59K 0.34% 85
2022
Q2 		$863K Buy
3,063
+173
+6% +$46.3K 0.34% 89
2022
Q1 		$754K Sell
2,890
-258
-8% -$61.2K 0.25% 110
2021
Q4 		$691K Buy
3,148
+135
+4% +$26.3K 0.22% 118
2021
Q3 		$547K Buy
3,013
+425
+16% +$83K 0.19% 127
2021
Q2 		$522K Buy
+2,588
New +$541K 0.18% 128
2013
Q3 		– Sell
-850
Closed -$68K – 378
2013
Q2 		$68K Buy
+850
New +$62.6K 0.05% 218

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Triangle Securities Wealth Management's VRTX Position: Q2 2026 in Review

Triangle Securities Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 1,709 shares worth $849K. The position accounts for 0.17% of the portfolio, ranked #125.

Triangle Securities Wealth Management first reported a position in VRTX in Q2 2013 and has held it in 22 quarters since. The position peaked at $863K in Q2 2022. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Triangle Securities Wealth Management held 1,709 shares of Vertex Pharmaceuticals worth $849K as of Q2 2026.
  • Triangle Securities Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.17% of Triangle Securities Wealth Management's portfolio in Q2 2026, its #125 holding.
  • Triangle Securities Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 22 quarters since.
  • Triangle Securities Wealth Management's Vertex Pharmaceuticals position peaked at $863K in Q2 2022.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Triangle Securities Wealth Management's 13F filing for Q2 2026, filed 14 Jul 2026.